ForPatients

by Roche

Healthy Volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03221179 WP39826

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The primary objective of this study is to evaluate the safety and tolerability of single ascending doses of subcutaneous (SC) injections of RO7049665 in healthy volunteers. In addition, pharmacokinetics (PK) of RO7049665, the effects of single doses of RO7049665 on regulatory T-cells as well as the single dose immunogenicity of RO7049665 will be evaluated. This trial plans to evaluate approximately seven single dose-levels of RO7049665 or matching-placebo during dose-escalation in approximately 40 participants.

Hoffmann-La Roche Sponsor	Phase 1 Phase	
NCT03221179 WP39826 Trial Identifiers		
Eligibility Criteria:		
Gender Male	Age >= 18 Years & <= 45 Years	Healthy Volunteers Accepts Healthy Volunteers